Research And Development In Biotechnology federal obligations in FY2025

How 541711 meets fiscal year 2025 in the award file

NAICS 541711 and fiscal year 2025 meet here. $371,157,048.60 is the USAspending.gov obligation sum on the yearlyTrend row that carries both tags. It is not Research And Development In Biotechnology's nationwide all-year total of $18,258,755,045.17, not every federal dollar coded to FY2025, and not an outlay register. FY2025 is a closed fiscal year in the yearlyTrend series used here; later ingests can still restate the cell.

FY2025 yearlyTrend is that fiscal year’s obligation sum tagged to NAICS 541711. A different fiscal year for the same code is a separate overlay. Calendar-year industry statistics are not this time key. Campaign-finance tables are a different dataset; donations do not fund these USAspending obligations. This cell is not a named-lab roster, a trial registry, or a molecule catalog.

What NAICS 541711 labels in FY2025

NAICS 541711 is Research And Development In Biotechnology. The code marks research and development in biotechnology. This packet lists no award recipients and no contractor names. Confusing this join with physical-engineering-life-sciences R&D or a trial-count dashboard would be a different table. Packet facts on the industry side are the name Research And Development In Biotechnology, code 541711, all-year obligations $18,258,755,045.17, and 473 awards. Any other recipient, program mix, or vendor list would be invented.

FY2025 on biotechnology R&D rows

Fiscal year 2025 is the yearlyTrend year key. It is not a calendar year and not a count of establishments in biotechnology r&d. Awards that carry a different year sit outside this cell even if the NAICS is still 541711. FY2025 obligations of $371,157,048.60 are about 2.0% of the industry’s $18,258,755,045.17 all-year obligation total in this extract — a thin slice of a large parent. Do not treat the all-year $18,258,755,045.17 as if it were the FY2025 headline.

473 awards as an industry table, not a lab census

The extract lists 473 awards on the Research And Development In Biotechnology table. That is an industry-level award-record count, not a FY2025-only census published on this packet. Dividing $371,157,048.60 by 473 would mix a year cell with an all-year row count, so this page does not treat that quotient as a typical FY2025 invoice. Unique vendors are unpublished. Modifications can add rows without naming a new company.

473 is the industry table’s award-record count in this extract, not a published FY2025-only recipient census. Unique vendors and places of performance are unpublished. Do not read 473 as 473 finished projects in biotechnology r&d.

Trial-count rankings the join cannot support

An obligation is a legal commitment. An outlay is a payment. $371,157,048.60 is the former. Citing it as cash already cleared in FY2025 over-reads the field. The join cannot say that FY2025 specialized in biotechnology r&d because of federal demand. Keep $371,157,048.60 labeled as Research And Development In Biotechnology obligations in FY2025. It is not a clinical-trial registry, an NIH Reporter list, or a nanotechnology R&D rollup.

Budget justifications, trade-association yearbooks, and private market-share reports answer other questions. They are not the source of this cell. If a chart mixes broader physical-engineering-life-sciences R&D labels this biotech code does not equal with NAICS 541711 in FY2025, the chart has left this join. Molecules, performers, and trial IDs are unpublished on this packet.

Reading Biotechnology R&D beside FY2025

Open the NAICS 541711 hub for the industry rollup, the FY2025 federal-spending hub for the fiscal-year rollup, the all-industries directory for other NAICS hubs, and the ties index for other pairs. None of those links convert this cell into physical-engineering-life-sciences R&D or a trial-count dashboard, into outlays this packet omits, or into a contractor list. Cite both sides: Research And Development In Biotechnology and FY2025, $371,157,048.60, USAspending.gov, obligations only. NAICS 541711 remains the industry key.

Questions

How much did Research And Development In Biotechnology show in federal obligations in FY2025?

USAspending.gov records $371,157,048.60 in Research And Development In Biotechnology obligations for FY2025 (NAICS 541711). That is an obligation aggregate for the industry-year pair, not an outlay and not the government-wide FY2025 total. Original filings remain on USAspending.gov.

Is biotechnology R&D FY2025 an outlay?

No. $371,157,048.60 is a yearlyTrend obligation sum, not an outlay. Payments from the Treasury can lag or differ. This packet has no outlay total for Research And Development In Biotechnology in FY2025. Original filings remain on USAspending.gov.

Does 473 awards mean 473 biotech labs?

No. 473 is the industry table’s award-record count in this extract, not a published FY2025-only recipient census. Unique vendors and places are unpublished. Modifications can add rows. Original filings remain on USAspending.gov. Keep both the NAICS code and the fiscal year in the citation.

Which pages parent Research And Development In Biotechnology FY2025?

The NAICS 541711 hub is the industry parent. The FY2025 federal-spending hub is the year parent. All industries lists NAICS hubs. All spending ties lists other pairs. Prefer those tables after later ingests; this page quotes Research And Development In Biotechnology × FY2025 at $371,157,048.60.